Dive brief:

• The medical technology industry is approaching 2026. in an improving position, with investors becoming more bullish and funding recovering, PitchBook said in its outlook for next year.
• PitchBook analysts said strategic investors are targeting companies nearing clinical stages in cardiology, orthopedics and diagnostics. Analysts identified neurostimulation, artificial intelligence-guided surgical navigation and precision medicine as other key areas to watch.
• Tariffs on Chinese-made components are a manageable and ongoing headwind, but the potential for higher tariffs is a risk, analysts said. PitchBook sees Medline’s an initial public offering is planned This is a strong indication that rate uncertainty is now less important.

Diving Insight:

Regardless slowing down In venture capital activity in the third quarter, the medtech industry continues a year of heavy investment by recent standards. PitchBook Predictions for 2026 reports that venture capital investment and private equity activity has increased as valuations fall and founders look to exit.

„After a two-year downward trend in capital allocation, investor tone is more upbeat, although selectivity remains high,” the analysts wrote in an outlook report. „Capital has focused on higher-quality assets rather than retreating completely, and strategic investors are once again picking up companies that are nearing clinical stages.”

The renewed commitment focused on cardiology, orthopedics and diagnostics, areas where companies such as Abbott, Boston Science and Zimmer Biomet PitchBook analysts expect that by 2026 there will be a „gradual acceleration of mergers and acquisitions”. The balance sheets of big medtech companies are healthy after two years of integrating previous acquisitions and spinning off units, analysts said.

Analysts said buyers will focus on „implementations that add AI or data-driven capabilities or can significantly improve scale compared to emerging competitors.” The report found that neurostimulation, smart implants and augmented reality surgery platforms are part of a new wave of technologies that are in the early stages of commercialization.

Mergers and acquisitions have historically been the main exit method for investors in medical technology companies. IPOs offer another option. Analysts said the IPO window is narrow. Analysts said Heartflow, Caris Life Sciences and BillionToOne have all gone public since June, but public market valuations have been mixed since their IPOs.

Analysts at Medline see the IPO as „a key test of investor appetite in the traditional, non-AI medical device space.” While the excitement around AI may have helped companies like Heartflow, which collected 364 million Medline is a more traditional medical technology company that sells about 335,000 products, including surgical and procedural kits, to commercialize software for creating 3D heart models.

Analysts at PitchBook said the global tariff situation has largely stabilized, with the exception of ongoing talks between the US and China. Analysts called the tariffs a manageable but persistent headwind on Chinese imports, adding that Article 232 investigation means that in 2026 Higher medical technology fees may apply.